Influx Health. (INFLUX)

Score breakdown: P/E: 1/3 · ROCE: 2/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

When I look at Influx Health, I see a business that demands attention but also caution. A 60.16% ROCE is extraordinary—it tells me management is deploying capital with remarkable efficiency, a hallmark of a business with some genuine economic moat, even if I cannot yet name its source. Sales are growing at 38.91% and profits at 78.11%, which is the kind of compounding that makes value investors sit up. The PEG ratio of 0.46 suggests that, despite a P/E of 27.17, the market may be underpricing the growth. Promoter holding of 73.53% aligns interests, and a Piotroski F-Score of 7/9 indicates solid financial health. But I must be skeptical. The latest quarter shows sales of ₹67 Cr and net profit of ₹10 Cr—yet trailing earnings imply only ~₹17.67 Cr annually. That single quarter contributes over half the year's profit, so either this is a seasonal spike or something non-repeatable. Without book value, ROE, or debt figures, I cannot fully assess the balance sheet risk. The dividend yield is zero, so returns must come purely from reinvestment and capital appreciation. At ₹275.65, with a 52-week range of ₹196.50 to ₹315.00, the stock is not at a distressed price. I would want to see if this growth is sustainable, whether the quarterly surge becomes the norm, and why the market is offering a PEG this low. If the moat holds and capital discipline continues, Influx could be a wonderful business. But for now, I watch, I learn, and I wait for more data.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer